Figure 5

YY1 nuclear expression correlated with poor survival in early stage gastric cancers. (A) Representative figures of YY1 immunohistochemistry in primary GACs. Left, negative/low expression case; right, positive expression case (original magnification × 100, insertion × 400). (B) YY1 nuclear expression predicted poor prognosis in early stage GAC patients (stage I and II, p = 0.045). (C) YY1 nuclear expression did not associate with disease specific survival in advanced stage GACs (stage III and IV, p = 0.958).